170 related articles for article (PubMed ID: 36271128)
1. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma.
Al-Ibraheem A; Anwer F; Juweid ME; Shagera QA; Khalaf AN; Obeidat S; Mansour A; Ma'koseh M; Halahleh K; Jaradat I; Almasri N; Mansour A
Sci Rep; 2022 Oct; 12(1):17702. PubMed ID: 36271128
[TBL] [Abstract][Full Text] [Related]
2. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.
Zaucha JM; Malkowski B; Chauvie S; Subocz E; Tajer J; Kulikowski W; Fijolek-Warszewska A; Biggi A; Fallanca F; Kobylecka M; Dziuk M; Woszczyk D; Rybka J; Kroll-Balcerzak R; Bergesio F; Romanowicz A; Chamier-Cieminska A; Kurczab P; Giza A; Lesniewski-Kmak K; Zaucha R; Swietlik D; Wróbel T; Knopinska-Posluszny W; Walewski J; Gallamini A
Ann Oncol; 2017 Dec; 28(12):3051-3057. PubMed ID: 28950332
[TBL] [Abstract][Full Text] [Related]
3. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.
Seshachalam A; Karpurmath SV; Rathnam K; Raman SG; Janarthinakani M; Prasad K; Patil C; Anoop P; Reddy N; Anumula SK; Roopa SP; Golamari KR; Danthala M; Gunari P; Malipatil B; Rangarajan B; Udupa KS; Nandennavar M; Niraimathi K; Shewade HD
J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31834832
[TBL] [Abstract][Full Text] [Related]
4. The frequency of change in five-point scale score with a Bayesian penalised likelihood PET reconstruction algorithm on interim FDG PET-CT and its potential implications for therapy decisions in Hodgkin's lymphoma.
Subesinghe M; Ilyas H; Dunn JT; Mir N; Duran A; Mikhaeel NG; Barrington SF
Clin Radiol; 2023 Feb; 78(2):e89-e98. PubMed ID: 36333130
[TBL] [Abstract][Full Text] [Related]
5. Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma.
Santos FM; Marin JFG; Lima MS; Silva-Junior WF; Alves LBO; Moreira FR; Velasques RD; Atanazio MJ; Maia ACA; Buchpiguel CA; Buccheri V; Rocha V
Ann Hematol; 2024 Jan; 103(1):175-183. PubMed ID: 37796339
[TBL] [Abstract][Full Text] [Related]
6. A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients.
Luminari S; Donati B; Casali M; Valli R; Santi R; Puccini B; Kovalchuk S; Ruffini A; Fama A; Berti V; Fragliasso V; Zanelli M; Vergoni F; Versari A; Rigacci L; Merli F; Ciarrocchi A
Clin Cancer Res; 2020 Jan; 26(2):373-383. PubMed ID: 31645353
[TBL] [Abstract][Full Text] [Related]
7. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
8. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
[TBL] [Abstract][Full Text] [Related]
9. The Utility of PET/CT in Guiding Radiotherapy Reduction for Children With Hodgkin Lymphoma Treated With ABVD.
Ingley KM; Nadel HR; Potts JE; Wilson DC; Eftekhari A; Deyell RJ
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e87-e93. PubMed ID: 31259825
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.
Sher DJ; Mauch PM; Van Den Abbeele A; LaCasce AS; Czerminski J; Ng AK
Ann Oncol; 2009 Nov; 20(11):1848-53. PubMed ID: 19541793
[TBL] [Abstract][Full Text] [Related]
11. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.
Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F
Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339
[TBL] [Abstract][Full Text] [Related]
12. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.
Ganeshan B; Miles KA; Babikir S; Shortman R; Afaq A; Ardeshna KM; Groves AM; Kayani I
Eur Radiol; 2017 Mar; 27(3):1012-1020. PubMed ID: 27380902
[TBL] [Abstract][Full Text] [Related]
13. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
14. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.
Song MK; Chung JS; Lee JJ; Jeong SY; Lee SM; Hong JS; Chong A; Moon JH; Kim JH; Lee SM; Kim SJ; Shin HJ
Cancer Sci; 2013 Dec; 104(12):1656-61. PubMed ID: 24033666
[TBL] [Abstract][Full Text] [Related]
15. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
16. A Ukrainian multicenter prospective study of the value of PET/ CT prognostic role in primary patients with Hodgkins lymphoma in a real-life cohort.
Novosad O; Skrypets T; Pastushenko I; Kadnikova T; Gorbach O; Kozlov V; Mykhalska L; Kosinova V; Kostiukova N; Karnabeda O; Stratienko V; Novikov M; Oliinichenko O; Kmetyuk I; Karpova O; Ashykhmin A; Lukjanec O; Kriachok I
Klin Onkol; 2020; 33(6):450-457. PubMed ID: 33685195
[TBL] [Abstract][Full Text] [Related]
17. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E
Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369
[TBL] [Abstract][Full Text] [Related]
18. Role of [18F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma.
Orlacchio A; Schillaci O; Gaspari E; Della Gatta F; Danieli R; Bolacchi F; Ragano Caracciolo C; Mancini A; Simonetti G
Radiol Med; 2012 Oct; 117(7):1250-63. PubMed ID: 22327919
[TBL] [Abstract][Full Text] [Related]
19. Combined prognostic role of TARC and interim
Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z
Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.
Cerci JJ; Pracchia LF; Linardi CC; Pitella FA; Delbeke D; Izaki M; Trindade E; Soares J; Buccheri V; Meneghetti JC
J Nucl Med; 2010 Sep; 51(9):1337-43. PubMed ID: 20720036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
